NHẬN XÉT TÌNH TRẠNG NÔN TRÊN NGƯỜI BỆNH UNG THƯ VÚ ĐANG ĐIỀU TRỊ BẰNG PHÁC ĐỒ HÓA CHẤT 4AC-4P TẠI BỆNH VIỆN K NĂM 2023

Abstract

Objectives: To describe the status of vomiting among breast cancer patients receiving the 4AC-4P regimen at K Hospital in 2023, and to analyze related to chemotherapy-induced vomiting (CINV). Materials and methods: A cross-sectional descriptive study was conducted on 136 patients from March to December 2023. Results: Among 136 breast cancer patients treated with the 4AC–4P regimen, the incidence of vomiting was 63.9%, mostly mild to moderate in severity. Early-onset vomiting occurred in 57.5% of patients, while delayed vomiting was more common (77%). Oral antiemetic supplementation significantly reduced vomiting rates (15.0% vs. 93.1%). Patients under 50 years of age were more likely to experience vomiting (75.0% vs. 48.2%, p=0.056). No statistically significant associations were found between vomiting and prior history of nausea/vomiting or pre-treatment counseling. Conclusions: Vomiting is a common side effect during chemotherapy with the 4AC–4P regimen. Oral antiemetic supplementation is effective in reducing vomiting. Although younger age may be associated with a higher risk of vomiting, other 4AC-4P such as prior history and counseling showed no significant imp4AC-4P. Symptom management is essential to improve patient quality of life during treatment.